UY36389A - COMPOSITIONS AND USES OF THE SAME FOR THE TREATMENT OF ULCERAS AND SYMPTOMS RELATED IN NON-HUMAN ANIMALS - Google Patents
COMPOSITIONS AND USES OF THE SAME FOR THE TREATMENT OF ULCERAS AND SYMPTOMS RELATED IN NON-HUMAN ANIMALSInfo
- Publication number
- UY36389A UY36389A UY0001036389A UY36389A UY36389A UY 36389 A UY36389 A UY 36389A UY 0001036389 A UY0001036389 A UY 0001036389A UY 36389 A UY36389 A UY 36389A UY 36389 A UY36389 A UY 36389A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- lechleri
- human animals
- ulcers
- enteric
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 3
- 241001648676 Croton lechleri Species 0.000 abstract 4
- 208000025865 Ulcer Diseases 0.000 abstract 4
- 231100000397 ulcer Toxicity 0.000 abstract 3
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 abstract 2
- 229920001991 Proanthocyanidin Polymers 0.000 abstract 2
- 229940069428 antacid Drugs 0.000 abstract 2
- 239000003159 antacid agent Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 2
- 239000000612 proton pump inhibitor Substances 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 206010022714 Intestinal ulcer Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 230000000112 colonic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002183 duodenal effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen métodos y composiciones para tratar y prevenir úlceras, condiciones ulcerativas y/o los síntomas de las mismas, incluyendo úlceras gástricas, intestinales, por ej. duodenales y colónicas en animales no humanos, especialmente caballos. Los métodos involucran tratar un animal afectado con composiciones que comprenden cantidades efectivas de una o más drogas que inhiben o reducen ácido, tales como antiácidos y/o inhibidores de la bomba de protones, y una cantidad terapéuticamente efectiva de un polímero de proantocianidina de Croton lechleri, o un extracto de Croton lechleri, ya sea en forma entérica o no entérica. Las composiciones de tratamiento de úlceras son formuladas como una pasta, gel o pasta de gel que contienen micropartículas asociadas que comprenden antiácido, inhibidor de la bomba de protones, y polímero de proantocianidina de C. lechleri o un extracto de C. lechleri, así como otros componentes, para particularmente proveer un sistema de suministro direccionado al colon para tratar y prevenir úlceras en animales que lo necesitan.Methods and compositions are provided to treat and prevent ulcers, ulcerative conditions and / or their symptoms, including gastric, intestinal ulcers, e.g. duodenal and colonic in non-human animals, especially horses. The methods involve treating an affected animal with compositions comprising effective amounts of one or more drugs that inhibit or reduce acid, such as antacids and / or proton pump inhibitors, and a therapeutically effective amount of a Croton lechleri proanthocyanidin polymer. , or an extract of Croton lechleri, either enteric or non-enteric. The ulcer treatment compositions are formulated as a paste, gel or gel paste containing associated microparticles comprising antacid, proton pump inhibitor, and proanthocyanidin polymer of C. lechleri or an extract of C. lechleri, as well as other components, in particular to provide a delivery system directed to the colon to treat and prevent ulcers in animals that need it.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074956P | 2014-11-04 | 2014-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36389A true UY36389A (en) | 2016-06-01 |
Family
ID=56009124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036389A UY36389A (en) | 2014-11-04 | 2015-11-04 | COMPOSITIONS AND USES OF THE SAME FOR THE TREATMENT OF ULCERAS AND SYMPTOMS RELATED IN NON-HUMAN ANIMALS |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160143879A1 (en) |
AR (1) | AR102529A1 (en) |
UY (1) | UY36389A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190151297A1 (en) * | 2016-04-29 | 2019-05-23 | Nauts Equine Brand Pty Ltd | Veterinary Composition |
WO2021072139A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
CN112546086A (en) * | 2020-12-21 | 2021-03-26 | 惠州市九惠制药股份有限公司 | Pharmaceutical composition for treating human colon cancer |
-
2015
- 2015-11-03 US US14/931,320 patent/US20160143879A1/en not_active Abandoned
- 2015-11-04 AR ARP150103574A patent/AR102529A1/en unknown
- 2015-11-04 UY UY0001036389A patent/UY36389A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20160143879A1 (en) | 2016-05-26 |
AR102529A1 (en) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002567A1 (en) | Compositions to modulate c9orf72 expression | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
EA201591327A1 (en) | SUBSTITUTED PYRROPOLYRIMIDIN COMPOUNDS, THEIR COMPOSITIONS AND TREATMENT METHODS USING SUCH CONNECTIONS | |
EA201691845A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
BR112017000301A2 (en) | treatment of leukemia with histone deacetylase inhibitors | |
CL2017000290A1 (en) | Protein kinase c inhibitors and methods of their use. | |
EA201890812A1 (en) | ADDITIONAL THERAPY 25-HYDROXIVITAMIN D AND PRODUCTS FOR THIS | |
CR20160308A (en) | COMBINATIONS OF INHIBITORS OF HISTONA DEACETILASE AND IMMUNOMODULATING PHARMACOS | |
EA201691844A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
MX2015016100A (en) | Cryopyrin inhibitors for preventing and treating inflammation. | |
EA201891514A1 (en) | COMBINED THERAPY BY THE BROMODOMENE INHIBITOR AND EXTRATERMINAL PROTEIN | |
AR093011A1 (en) | FOOD FOR ANIMALS THAT REDUCES AMMONIA CONCENTRATIONS IN ITS EXCREMENTS | |
CL2017001025A1 (en) | Compounds for use in anthelmintic treatment | |
MX2021004558A (en) | Proton-binding polymers for oral administration. | |
CL2015002319A1 (en) | Device and system for the treatment of fish. | |
CL2017003133A1 (en) | Use of benzimidazole derivatives for night acid escape | |
EA201791933A1 (en) | INHIBITION OF OLIG2 ACTIVITY | |
UY37980A (en) | NOVELTY COMPOUNDS TO TREAT PARASITIC DISEASES | |
UY36389A (en) | COMPOSITIONS AND USES OF THE SAME FOR THE TREATMENT OF ULCERAS AND SYMPTOMS RELATED IN NON-HUMAN ANIMALS | |
EA201791225A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION OF SOLABEGRON WITH MODIFIED RELIEF AT THE SYMPTOMS OF THE LOWER BLANK | |
ZA201901367B (en) | Inhibition of olig2 activity | |
MX2017016671A (en) | Isoxazoline solution containing vitamin e for use with sanitized drinking water. | |
UY36196A (en) | COMPOUNDS TO USE IN ANTIHELMINTIC TREATMENT | |
CO2017001899A2 (en) | Cancer treatment with alpha-amylase inhibitor in companion animals | |
CO2017007823A2 (en) | Compositions for treating diarrhea in pets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |